TScan Therapeutics, Inc.

TCRX

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001783328

SEC filings (opens in a new tab)

No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding TScan Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022 All holders in Q2 2022

13F holders of TCRX: Q2 2022 compared with Q3 2022
Measure	Q2 2022	Q3 2022	Change
Holders	24	26	+2
Shares	9.68M	9.51M	−173.8K (−1.8%)
Value	$30.4M	$29.0M	−$1.45M (−4.7%)

New holders (3)

Institutions that held TScan Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to TCRX in Q3 2022
Institution	Shares	Value	% of portfolio
Privium Fund Management (UK) Ltd	15,825	$48.0K	0.06%
Prudential Financial Inc	11,000	$34.0K	0.00%
Royal Bank of Canada	184	$1.00K	0.00%

Sold out (1)

Institutions that held TScan Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of TCRX in Q3 2022
Institution	Shares, Q2 2022	Value, Q2 2022
Jane Street Group, LLC	10,176	$32.0K